Yttrium [90Y] Ferric Hydroxide Colloid

What is Yttrium [90Y] Ferric Hydroxide Colloid?

Yttrium [90Y] Ferric Hydroxide Colloid is a unique radiopharmaceutical used in nuclear medicine for the treatment of chronic inflammatory joint conditions. It consists of small particles of ferric hydroxide labeled with Yttrium-90 (⁹⁰Y), a pure beta-emitting radioisotope. This colloid is designed for targeted therapy, specifically for a procedure known as radiosynovectomy, where it delivers localized radiation to the synovial membrane of an affected joint. Unlike systemic treatments, its action is confined to the site of injection, aiming to reduce inflammation and pain with minimal systemic exposure. It represents an important therapeutic option for patients who have not responded adequately to conventional treatments.

How Does it Work?

The therapeutic mechanism of Yttrium [90Y] Ferric Hydroxide Colloid relies on its radioactive properties and targeted delivery. Once injected directly into an inflamed joint, the colloid particles are rapidly absorbed and phagocytosed by the macrophages and other cells within the synovial membrane, which is the lining of the joint capsule. Yttrium-90 then emits high-energy beta radiation. This radiation has a short tissue penetration range (typically a few millimeters), which allows it to selectively destroy the hyperactive, inflamed synovial tissue without significantly affecting surrounding healthy cartilage or bone. The destruction of the inflamed synovium helps to reduce inflammation, decrease pain, and improve joint function over time. The half-life of Yttrium-90 is approximately 64 hours, ensuring that the radioactive effect is localized and relatively short-lived.

Medical Uses

The primary medical use of Yttrium [90Y] Ferric Hydroxide Colloid is in the treatment of various forms of chronic synovitis that have proven resistant to conservative therapies. This condition involves persistent inflammation of the synovial membrane, leading to pain, swelling, and reduced joint mobility. Key indications include:

• Rheumatoid arthritis: Especially for persistent inflammation in specific joints despite systemic medication.
• Psoriatic arthritis: For individual joints affected by chronic synovitis.
• Hemophilic arthropathy: To manage recurrent bleeding and inflammation in joints.
• Pigmented villonodular synovitis (PVNS): As an adjuvant therapy after surgical removal of the affected tissue.
• Recurrent joint effusions: When fluid accumulation persists due to inflammation.

Radiosynovectomy with this colloid is typically considered when other treatments, such as oral anti-inflammatory drugs, corticosteroid injections, or disease-modifying antirheumatic drugs (DMARDs), have failed to provide lasting relief or are contraindicated.

Dosage

The administration of Yttrium [90Y] Ferric Hydroxide Colloid is a specialized procedure performed by a physician experienced in nuclear medicine or rheumatology. The dosage is carefully determined based on the size of the joint being treated. Typical dosages are:

• Large joints (e.g., knee, hip, shoulder): 185 MBq (Mega Becquerel)
• Medium joints (e.g., elbow, wrist, ankle): 90 MBq
• Small joints (e.g., fingers, toes): 30 MBq

The colloid is administered as a single intra-articular injection directly into the joint space. To minimize the risk of leakage from the joint and potential skin irritation or local radiation exposure, it is often recommended to immobilize the treated joint for 48-72 hours post-injection. Pre-treatment imaging, such as ultrasonography or fluoroscopy, may be used to ensure accurate placement of the needle and to confirm that the colloid remains within the joint capsule.

Side Effects

While generally well-tolerated, treatment with Yttrium [90Y] Ferric Hydroxide Colloid can lead to some side effects. Most are localized and temporary:

• Common side effects: Temporary increase in joint pain, swelling, warmth, or stiffness at the injection site, usually lasting a few days.
• Less common side effects:
• Allergic reactions (rare).
• Skin necrosis or ulceration if the colloid leaks out of the joint capsule.
• Infection within the joint (extremely rare, but a risk with any injection).
• Radiation-induced changes to the cartilage or bone, though rare with proper dosing and confinement.

Patients should immediately report any severe or persistent pain, redness, fever, or signs of infection to their healthcare provider. Due to its radioactive nature, it is contraindicated during pregnancy and breastfeeding, and women of childbearing potential should use effective contraception before and after treatment.

Drug Interactions

Given that Yttrium [90Y] Ferric Hydroxide Colloid is administered as a localized intra-articular injection, its systemic absorption is minimal, and therefore, significant drug interactions with systemic medications are generally not expected. The colloid primarily exerts its effects locally within the joint. However, it is crucial for patients to inform their healthcare provider about all medications they are currently taking, including prescription drugs, over-the-counter medicines, herbal supplements, and vitamins. This information helps the doctor to assess the overall health status and ensure there are no contraindications or specific considerations related to the patient's existing treatment regimen, especially regarding other anti-inflammatory or immunosuppressive therapies for their joint condition.

FAQ

Is the injection of Yttrium [90Y] Ferric Hydroxide Colloid painful?

The injection itself might cause some discomfort, similar to any joint injection. Local anesthetic is often used to numb the area before the procedure. Post-injection, it's common to experience a temporary increase in joint pain or swelling for a few days, which can usually be managed with standard pain relievers.

How long does it take for Yttrium [90Y] Ferric Hydroxide Colloid to work?

The therapeutic effects are not immediate. Patients typically begin to experience improvement in pain and swelling within a few weeks to several months after the procedure. The full benefits may take up to six months to become apparent.

How many treatments can I receive?

Radiosynovectomy is usually a single treatment per affected joint. Repeat treatments in the same joint are generally not recommended due to potential risks of radiation-induced damage, but may be considered in very specific circumstances and after careful evaluation by a specialist.

Is it safe to be around other people after the treatment?

Yes, Yttrium-90 is a pure beta emitter with a very short range, meaning the radiation does not penetrate far outside the body. While some minor precautions might be advised for very close contact immediately after the procedure, there is generally no significant risk to others, and patients can typically resume normal social interactions.

Products containing Yttrium [90Y] Ferric Hydroxide Colloid are available through trusted online pharmacies. You can browse Yttrium [90Y] Ferric Hydroxide Colloid-based medications at ShipperVIP or Medicenter.

Summary

Yttrium [90Y] Ferric Hydroxide Colloid offers a targeted and effective therapeutic option for patients suffering from persistent chronic synovitis, particularly those with rheumatoid arthritis and other inflammatory joint conditions unresponsive to conventional treatments. Administered via intra-articular injection, this radiopharmaceutical delivers localized beta radiation to the inflamed synovial membrane, reducing inflammation, alleviating pain, and improving joint function. While potential side effects are typically localized and transient, its precise application under specialist supervision ensures a favorable risk-benefit profile, providing significant relief and enhanced quality of life for many patients.